Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Roseburia intestinalis sensitizes colorectal cancer to radiotherapy through butyrate/OR51E1/RALB axis

PROVIDER: PRJNA1067426 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27675810.fastq.gz	Fastqsanger.gz
	SRR27675811.fastq.gz	Fastqsanger.gz
	SRR27675812.fastq.gz	Fastqsanger.gz
	SRR27675813.fastq.gz	Fastqsanger.gz
	SRR27675814.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 42

Similar Datasets

Radiotherapy for CRC (FMT)

Project description:Roseburia sensitizes colorectal cancer to radiotherapy

| PRJEB45422 | ENA

The Human Gut Firmicute Roseburia intestinalis is a Primary Degrader of Dietary β-Mannans

Project description:β-Mannans are plant cell wall polysaccharides that are commonly found in human diets. However, a mechanistic understanding into the key populations that degrade this glycan is absent, especially for the dominant Firmicutes phylum. Here, we show that the prominent butyrate-producing Firmicute Roseburia intestinalis expresses two loci conferring metabolism of β-mannans. We combine multi-“omic” analyses and detailed biochemical studies to comprehensively characterize loci-encoded proteins that are involved in β-mannan capturing, importation, de-branching and degradation into monosaccharides. In mixed cultures, R. intestinalis shares the available β-mannan with Bacteroides ovatus, demonstrating that the apparatus allows coexistence in a competitive environment. In murine experiments, β-mannan selectively promotes beneficial gut bacteria, exemplified by increased R. intestinalis, and reduction of mucus-degraders. Our findings highlight that R. intestinalis is a primary degrader of this dietary fiber and that this metabolic capacity could be exploited to selectively promote key members of the healthy microbiota using β-mannan-based therapeutic interventions.

2019-02-21 | PXD012448 | Pride

Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model

Project description:Background: Humans with metabolic and inflammatory diseases frequently harbor lower levels of butyrate-producing bacteria in their gut. However, it is not known whether variation in the levels of these organisms is causally linked with disease development and whether diet modifies the impact of these bacteria on health. Results: We use germ-free apolipoprotein E-deficient mice colonized with synthetic microbial communities that differ in their capacity to generate butyrate to demonstrate that Roseburia intestinalis interacts with dietary components to (i) impact gene expression in the intestine, directing metabolism away from glycolysis and toward fatty acid utilization, (ii) improve intestinal barrier function, (iii) lower systemic inflammation and (iv) ameliorate atherosclerosis. Furthermore, intestinal administration of butyrate improves gut barrier function and reduces atherosclerosis development. Conclusions: Altogether, our results illustrate how modifiable diet-by-microbiota interactions impact cardiovascular disease, and suggest that interventions aimed at increasing the representation of butyrate-producing bacteria may provide protection against atherosclerosis.

2018-08-29 | GSE119141 | GEO

Roseburia intestinalis

Project description:Roseburia intestinalis overview

| PRJNA37527 | ENA

Project description:Xylan utilization by Roseburia intestinalis

| PRJNA516365 | ENA

Roseburia intestinalis CAG:13

Project description:Roseburia intestinalis CAG:13 overview

| PRJNA207151 | ENA

Effect of sodium butyrate on colorectal cancer cell line HT-29

Project description:Analysis of colorectal cancer (CRC) cell line HT-29 treated with Sodium Butyrate. Sodium Butyrate, a HDAC inhibitor present in gut, can differentiate the undifferentiated HT-29 to enterocytes by the induction of brush border enzyme alkaline phosphatase. Results provide the transcriptional profiling underlying the butyrate-induced differentiation of CRC.

2016-12-31 | GSE61429 | GEO

Project description:β-Mannan utilization by Roseburia intestinalis

| PRJNA516396 | ENA

Roseburia intestinalis XB6B4

Project description:Roseburia intestinalis XB6B4 genome sequencing project

| PRJNA45953 | ENA

Roseburia intestinalis M50/1

Project description:Roseburia intestinalis M50/1 genome sequencing project

| PRJNA39165 | ENA